Spectral Medical Inc. (TSX: EDT)
Canada
· Delayed Price · Currency is CAD | Market Cap | 139.29M |
| Revenue (ttm) | 1.74M |
| Net Income (ttm) | -18.05M |
| Shares Out | 278.64M |
| EPS (ttm) | -0.06 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 116,400 |
| Open | 0.500 |
| Previous Close | 0.490 |
| Day's Range | 0.500 - 0.530 |
| 52-Week Range | 0.225 - 0.670 |
| Beta | 0.91 |
| Analysts | n/a |
| Price Target | 1.80 (+260.0%) |
| Earnings Date | Aug 8, 2024 |
About Spectral Medical
Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrat... [Read more]
Financial Performance
In 2023, EDT's revenue was 1.60 million, a decrease of -4.14% compared to the previous year's 1.67 million. Losses were -15.66 million, 38.6% more than in 2022.
Financial StatementsNews
Spectral Medical GAAP EPS of -C$0.01, revenue of C$0.67M
Spectral Medical Announces First Quarter Results and Provides Corporate Update
Tigris Trial Enrollment Reaches 106 Patients Bought Deal Financing Expected to Fund Completion of Tigris Trial Enrollment TORONTO, May 13, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or...
Spectral Medical Inc. Announces C$8.5 Million Bought Deal Convertible Note Financing
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES OF AMERICA OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF...
Spectral Medical Provides April Tigris Trial Update
• 105 patients enrolled • April represents a record breaking month for patient enrollment TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT),...
Spectral Medical Provides Tigris Trial Update
TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, ...
Spectral Medical reports Q4 results
Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update
TORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, ...
Spectral Medical Provides February Tigris Trial Update
TORONTO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical Provides Early February Tigris Trial Update
TORONTO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical Provides January Tigris Trial Update
TORONTO, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical says CFO McInnis to resign
Spectral Medical announces CFO Blair McInnis's resignation, and Chris Seto will serve as the interim CFO while the company conducts a formal search.
Spectral Medical GAAP EPS of -C$0.01, revenue of C$0.4M
Spectral Medical Q3 results show a slight decrease in EPS but positive revenue growth, indicating potential stability in the financial performance.
Spectral Medical Announces Third Quarter Results and Provides Corporate Update
Tigris Trial Enrollment Reaches 76 Patients Crude mortality results continue to exceed expectations TORONTO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX:...
Spectral Medical Announces Second Quarter Results and Provides Corporate Update
TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, t...
Spectral Medical Announces First Quarter Results and Provides Corporate Update
New Trial Sites Enroll 60% of New Patient Enrollments Since the Beginning of April Tigris Patient Enrollment at 58 Patients TORONTO, May 12, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” ...
Spectral Medical Announces Investor Update Conference Call
TORONTO, April 06, 2023 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, ...
Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update
Reports significant enhancements to accelerate Tigris patient enrollment including appointment of new Contract Research Organization
Spectral Announces Second Quarter Results and Provides Corporate Update
TORONTO, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, a...
Spectral Announces First Quarter Results and Provides Corporate Update
TORONTO, May 14, 2021 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as...
Spectral Announces Third Quarter Results
Dialco's DIMI receives FDA 510(k) clearance for use in hospital and clinical settings – a significant step in the full regulatory development of DIMI